@BioPharmaDive

We provide in-depth insight into the most significant news and trends shaping biotech and pharma. Sign up here: https://xitter.cf/t.co/sTgs1kxwYE

 Washington, D.C.
BioPharmaDive.com
Joined July 2013
  • Tweets18.1K
  • Following308
  • Followers14K
243Media
Get the latest biotech & pharma intel in your inbox for free. Our newsletters cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. Sign up today: biopharmadive.com/link/6547/…

BioPharma Dive Newsletter

Sign up for BioPharma Dive: The free email newsletter covering the top news and trends for biotech and pharma industry leaders.

biopharmadive.com
3
2,395
This week in charts: a big year for RNAi developers biopharmadive.com/news/chart… by @Lilah_Alvarado

This week in charts: a big year for RNAi developers

The latest installment in BioPharma Dive’s data visualization series features a look at the emerging popularity of RNAi developers, and the funding that came with it.

biopharmadive.com
2
521
Protein degrader specialist Lycia prices $318M IPO biopharmadive.com/news/lycia… $LYCA BY @gwendolynawu

Protein degrader specialist Lycia prices $318M IPO

Funds from the upsized offering will support a trio of protein-degrading medicines in development for allergic conditions as well as the autoimmune disorder Graves’ disease.

biopharmadive.com
1
658
Star adds $200M after spinout successes biopharmadive.com/news/star-… by @gwendolynawu

Star adds $200M after spinout successes

Following exits for its subsidiaries Electra Therapeutics and Vega Therapeutics, Star is now mining for a new drug prospect.

biopharmadive.com
1
1
458
Moderna, Merck shares fall on eagerly anticipated cancer vaccine results biopharmadive.com/news/moder… $MRK $MRNA @ByJonGardner

Moderna, Merck shares fall on eagerly anticipated cancer vaccine results

A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study that met Wall Street expectations but triggered a “sell-the-news reacti...

biopharmadive.com
1
1
4
824
Biohaven’s previously rejected rare disease drug to get fresh FDA review biopharmadive.com/news/bioha… $BHVN by @Lilah_Alvarado

Biohaven’s previously rejected rare disease drug to get fresh FDA review

U.S. regulators have accepted a new submission for Vyglxia, offering the chance at a turnaround for another rare disease medicine spurned by previous FDA leadership.

biopharmadive.com
2
1
579
Roche affirms sales outlook amid doubts about its future biopharmadive.com/news/roche… $ROCH.NE By Kristin Jensen

Roche affirms sales outlook amid doubts about its future

Lower-than-expected sales of Xolair stood out as the Swiss drugmaker readies for an onslaught of generic competition for top products. 

biopharmadive.com
1
474
GLP-1 compounder issues recall for copycat Zepbound biopharmadive.com/news/glp1-… @ByJonGardner

GLP-1 compounder issues recall for copycat Zepbound

The notice adds to growing concerns about the safety of knockoff weight loss drugs, which have remained popular despite FDA warnings and legal pressure from Eli Lilly and Novo.

biopharmadive.com
1
1
511
Roivant, continuing ascent, claims another victory for rare disease drug biopharmadive.com/news/roiva… $ROIV By Kristin Jensen

Roivant, continuing ascent, claims another victory for rare disease drug

Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also be a “best-in-disease” medicine for an inflammatory eye condition, one...

biopharmadive.com
2
532
GSK, Ionis win US approval for first-of-its-kind hepatitis B drug biopharmadive.com/news/gsk-i… $GSK $IONS by @Lilah_Alvarado

GSK, Ionis win US approval for first-of-its-kind hepatitis B drug

Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s goal of reaching £40 billion in annual revenue by 2031.

biopharmadive.com
2
1
2
701
News Roundup: Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal biopharmadive.com/news/arcus…

Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal

New follow-up results suggest Arcus’ drug might be superior to a marketed Merck medicine. Elsewhere, Eli Lilly and AstraZeneca forged new partnerships.

biopharmadive.com
1
1
488
Rapport’s epilepsy drug finds surprising success in bipolar trial biopharmadive.com/news/rappo… $RAPP by @realJacobBell

Rapport’s epilepsy drug finds surprising success in bipolar trial

Despite what some analysts described as low expectations, RAP-219 narrowly hit the main goal of a mid-stage study, results that could help it tap a billion-dollar-plus market opportunity.

biopharmadive.com
2
4
959
Most new drugs are still too costly at launch, ICER says biopharmadive.com/news/icer-… @ByJonGardner

Most new drugs are still too costly at launch, ICER says

A new analysis from the non-profit group found that net launch prices for new medicines spiked significantly between 2022 and 2025, and the majority were well above its cost-effectiveness guidelines....

biopharmadive.com
2
529
News Roundup: Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study biopharmadive.com/news/roche…

Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study

Roche is paying Hansoh $400 million up front in a broad deal involving several ADCs. Elsewhere, another top investor formed a China-focused fund and Ultragenyx sold a second review voucher.

biopharmadive.com
1
601
Disc’s once-spurned rare disease drug to get a second chance at approval biopharmadive.com/news/Disc-… $IRON by @Lilah_Alvarado

Disc’s once-spurned rare disease drug to get a second chance at approval

Months after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 trial and now plans to re-engage regulators.

biopharmadive.com
2
1
2
725
Merck KGaA bets on RNAi with $1.3B Silence buyout biopharmadive.com/news/merck… $MKKGY @ByJonGardner

Merck KGaA bets on RNAi with $1.3B Silence buyout

The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.

biopharmadive.com
1
4
650
Iambic CEO on taking an AI drug company public biopharmadive.com/news/Iambi… $IAM by @realJacobBell

Iambic CEO on taking an AI drug company public

Fresh off a $150 million IPO, Tom Miller spoke to BioPharma Dive about the roadshow process and how he sees AI’s role in drug development evolving.

biopharmadive.com
1
660
Biogen-backed Estuary nabs $93M for kidney disease gene therapy biopharmadive.com/news/estua… by @realJacobBell

Biogen-backed Estuary nabs $93M for kidney disease gene therapy

The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an inherited kidney disorder known as "ADPKD."

biopharmadive.com
1
2
601
This week in charts: Moderna’s massive stock run biopharmadive.com/news/biote… $MRNA by @Lilah_Alvarado

This week in charts: Moderna’s massive stock run

The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.

biopharmadive.com
1
737
Next-gen RNAi drugmaker City prices $200M IPO biopharmadive.com/news/city-… $CTY by @Lilah_Alvarado

Next-gen RNAi drugmaker City prices $200M IPO

The offering will support a trio of medicines in or nearing clinical testing, as well as earlier research into RNAi treatments that get into tissues outside the liver. 

biopharmadive.com
2
1
2
1,033
Belgian startup revives Galapagos CAR-T research biopharmadive.com/news/lakef… @ByJonGardner

Belgian startup revives Galapagos CAR-T research

Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of cell therapies the company — now known as Lakefront Biotherapeutics — divested in a strategic overhaul.

biopharmadive.com
1
557
Load more